US › Healthcare

Pmv Pharmaceuticals Inc (PMVP)

US · Healthcare · Biotechnology

$1.17+4.46%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-18.0M
Profit YoY
-3.5%
EPS
$-0.34
EPS estimate
$-0.38

EPS came in at -0.34 against a street estimate of -0.38 — a beat of 10.5%.

Key statistics

Market cap
$59.2M
Forward P/E
0.0
P/B
0.68
Book value
$1.65
EPS (TTM)
$-1.48
52-week high
$1.88
52-week low
$1.02
50-day MA
$1.21
200-day MA
$1.29
Beta
1.33

Analyst view

Analysts rate Pmv Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $4.00.

Shareholding

Insiders
3.35%
Institutions
66.88%

Largest institutional holders

FundStake
BML Capital Management LLC9.98%
TANG CAPITAL MANAGEMENT LLC7.96%
Sio Capital Management, LLC5.77%
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)5.39%
Euclidean Capital LLC4.93%
Eversept Partners, LP4.40%
Acadian Asset Management LLC4.15%
Vanguard Capital Management, LLC3.70%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pmv Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.